Studies related to Anxiety and Curcumin

Curcumin For The Treatment Of Major Depression: A Randomised, Double-blind, Placebo Controlled Study

Effect Decrease
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 56
Sex Both Genders
Age Range 18-29, 30-44, 45-64
Body Types Average
Notes for this study:
A total of 56 individuals with MDD were treated with 500 mg of BCM-95 curcumin (twice daily) or placebo for eight weeks. The primary measure was the IDS-SR30. Secondary outcomes included IDS-SR30 factor scores and the STAI. After eight weeks, The curcumin group experienced a 33.1% decrease in IDS-SR30 scores, a 19% decrease in STAI-S scores and a 14.8% decrease in STAI-T scores.
Funding issues for this study:
Funding for this study was provided by Arjuna Natural Extracts Limited.

Full details on all 4 studies are available to Examine Members. Try out the Examine Membership with a 14-day free trial.

Already a Member? Log in now to access.